Literature DB >> 1590911

Clinical heterogeneity of probable Alzheimer's disease.

K Blennow1, A Wallin.   

Abstract

When the symptomatology in probable Alzheimer's disease (AD) was studied, two subgroups emerged: one with predominant cortical symptoms of parietal type (AD type I) and another with general cognitive symptoms but absence of or only mild cortical symptoms (AD type II). In AD type I, the age at onset was significantly lower, confusional symptoms and leukoariosis on computerized tomographic scan were less frequent, and the ganglioside GM1 concentration in cerebrospinal fluid was significantly higher than in AD type II. Although the significance of changes in cerebrospinal fluid gangliosides has not been fully elucidated, it is possible that the increase in cerebrospinal fluid GM1 reflects a more severe degeneration of neurons and synapses in AD type I than in AD type II. The relation between symptomatology and leukoariosis suggests that leukoariosis has clinical significance in AD patients. The total results suggest heterogeneity of probable AD. AD type I appears to constitute a classic AD subgroup with memory disturbances and marked cortical symptoms of parietal type, while age-related changes, vascular changes, and leukoariosis may be responsible for the more generalized symptomatology in AD type II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590911     DOI: 10.1177/002383099200500208

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  7 in total

Review 1.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

2.  Clinical features of leuko-araiosis.

Authors:  S Tarvonen-Schröder; M Röyttä; I Räihä; T Kurki; T Rajala; L Sourander
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality.

Authors:  I Skoog; C Hesse; O Aevarsson; S Landahl; J Wahlström; P Fredman; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

4.  Associations Between Depression, Traumatic Brain Injury, and Cognitively-Defined Late-Onset Alzheimer's Disease Subgroups.

Authors:  Julianna Bauman; Laura E Gibbons; Mackenzie Moore; Shubhabrata Mukherjee; Susan M McCurry; Wayne McCormick; James D Bowen; Emily Trittschuh; Maria Glymour; Jesse Mez; Andrew J Saykin; Kristen Dams-O'Conner; David A Bennett; Eric B Larson; Paul K Crane
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 5.  The Amyloid-β Pathway in Alzheimer's Disease.

Authors:  Harald Hampel; John Hardy; Kaj Blennow; Christopher Chen; George Perry; Seung Hyun Kim; Victor L Villemagne; Paul Aisen; Michele Vendruscolo; Takeshi Iwatsubo; Colin L Masters; Min Cho; Lars Lannfelt; Jeffrey L Cummings; Andrea Vergallo
Journal:  Mol Psychiatry       Date:  2021-08-30       Impact factor: 15.992

6.  Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.

Authors:  Tobias Skillbäck; Henrik Zetterberg; Kaj Blennow; Niklas Mattsson
Journal:  Alzheimers Res Ther       Date:  2013-10-14       Impact factor: 6.982

7.  Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013.

Authors:  Gérard Siest; Edith Schallmeiner
Journal:  EJIFCC       Date:  2013-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.